TrialAnnals of the rheumatic diseases2017

Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial.

Tatsuya Atsumi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.